Figure 3.

and excess burden of post-acute COVID-19 kidney outcomes at 6 months in mutually exclusive cohorts of Veterans with non-hospitalized COVID-19, those hospitalized with COVID-19 with no evidence of an AKI, and those hospitalized with COVID-19 with an AKI during the first 30 days (acute phase) of the infection. Participants who had COVID-19 were compared with users of the VHA healthcare system who had no record of a positive COVID-19 test (control group). Outcomes were ascertained starting from 30 days after the participant’s positive COVID-19 test through end of follow-up. Unadjusted incident rates per 1000 person-years, HRs, and excess burden per 1000 persons at 6 months are provided for each COVID-19 group (non-hospitalized, hospitalized without an AKI, and hospitalized with an AKI during the acute phase of the infection). HRs and corresponding 95% CIs are plotted. MAKE was defined as a composite of eGFR decline ≥50%, ESKD, or all-cause mortality. All models were adjusted for a set of 29 predefined variables and 100 variables selected by a high-dimensional variable selection algorithm.